ClinConnect ClinConnect Logo
Search / Trial NCT05137743

Pilot Test of Apnea and Insomnia Relief for Veterans With Gulf War Illness

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Nov 16, 2021

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at whether a special sleep treatment can help improve sleep and other health issues for veterans with Gulf War Illness (GWI). The study is specifically for veterans aged 48 to 80 who served in the Gulf region and have symptoms like fatigue, pain, mood changes, or sleep problems. To participate, veterans must have a diagnosis of insomnia and obstructive sleep apnea, which is a condition that affects breathing during sleep. The trial is currently recruiting volunteers, and both men and women are eligible to join.

Participants in the study can expect to receive behavioral therapy aimed at improving their sleep over six weeks, along with follow-up support for three months. Researchers believe that better sleep may also help ease other symptoms related to Gulf War Illness. It’s important to note that veterans with certain medical or psychiatric conditions that could interfere with their ability to participate will not be eligible, but those with a history of PTSD or depression may still join as long as they haven’t been hospitalized recently. This trial aims to offer hope for better sleep and overall health for veterans dealing with the challenges of Gulf War Illness.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male and female GW Veterans between the ages of 48-80
  • Deployed to the "Gulf Theater of operations," as defined by 38 CFR 3.317
  • Meets the Kansas GWI and Centers for Disease Control and Prevention (CDC) Chronic Multisymptom Illness (CMI) case definitions. The Kansas GWI definition requires cases to endorse multiple or moderate-to-severe chronic symptoms in at least three of six symptom domains. These include: i) fatigue/sleep problems, ii) somatic pain, iii) neurological cognitive, mood symptoms, iv) gastrointestinal symptoms, v) respiratory symptoms, and vi) skin abnormalities. Veterans will be excluded from being considered Kansas GWI cases, for purposes of the proposed trial, if they report being diagnosed by a physician with medical or psychiatric conditions that would account for their symptoms or interfere with their ability to report their symptoms. Veterans with current or past history of PTSD or depression in the past 5 years will not be excluded from participation if they have not been hospitalized for these conditions. The CDC CMI case definition requires cases to endorse symptoms in at least two of three symptom clusters. These include: i) fatigability (e.g., feeling fatigue for 24 hours or more after exertion), ii) mood/cognitive symptoms (e.g., feeling depressed, irritable, worried, tense or anxious; difficulty thinking or concentrating, problems finding words, or problems getting to or staying asleep). iii) musculoskeletal pain.
  • Meet the DSM-5 research diagnostic criteria for insomnia disorder. Unlike other GWI symptoms, we will not require the Veteran's insomnia to have begun during the Gulf War or within one year after leaving the Gulf region. This is because some GWI symptoms may cause veterans to adopt behaviors that lead to sleep problems later. Results from our CBT-I trial in Veterans with GWI suggest that improving sleep also improves non-sleep related symptoms such as fatigue, depression, pain, and psychosocial function. Therefore, we hypothesize that even if insomnia was not one of the original GWI symptoms, improving sleep in veterans with GWI will also improve other GWI-related symptoms.
  • Diagnosed with obstructive sleep apnea (OSA) by physician based on polysomnography or evidence of OSA based on an Apnea-Hyponea Index (AHI) or respiratory disturbance index (RDI) that is \> or = 5 based on home sleep apnea testing.
  • Have access to wireless internet connection at home for remote positive airway pressure (PAP) data capture.
  • Exclusion Criteria:
  • Condition(s) that is/are considered exclusionary for the Kansas GWI criteria. For purposes of this trial, this will include medical or psychiatric conditions diagnosed by a physician/psychiatrist that would account for the Veterans' symptoms or interfere with their ability to report their symptoms. Specific exclusionary criteria include medical conditions such as uncontrolled diabetes, heart disease other than hypertension, stroke, lupus, multiple sclerosis, cancer, liver disease, chronic infection, or serious neurological condition (e.g., dementia, brain injury).
  • History of any psychiatric disorder with active psychosis or mania in the past 5 years.
  • Severe drug or alcohol use disorder within the past 6 months as assessed by the Structured Clinical Interview for DSM-5 (SCID 5). Veterans with moderate drug or alcohol use disorder will be reviewed on a case-by-case basis.
  • Prominent suicidal or homicidal ideation.
  • Pregnancy, because insomnia will worsen after 8 weeks.
  • Restless Legs Syndrome (RLS) or screening indicative of RLS based on Restless legs syndrome screening questionnaire (RLSSQ).
  • Current enrollment in another clinical trial.
  • Traumatic brain injury (TBI) will not be exclusionary for the proposed study unless it impacts cognition to a degree that the Veteran cannot complete treatment or homework assignments (this will be determined on a case-by-case basis at PI and therapists' discretion).
  • Starting or ending psychotherapy for a sleep disorder or mental health diagnosis within the last one month.
  • Starting or ending an antidepressant, anxiolytic, or sleep medication with the last one month will be excluded. Veterans currently receiving benzodiazepine or benzodiazepine receptor agonists, anticonvulsants, atypical antipsychotic medication, or non-SSRI antidepressant medications such as trazodone will be not be excluded provided that they meet the DSM-5 criteria for insomnia disorder, exhibit evidence of OSA, and will remain on the medication(s) throughout the 6-week treatment period and the 3-month follow-up period.

About University Of California, San Francisco

The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.

Locations

San Francisco, California, United States

Patients applied

0 patients applied

Trial Officials

Linda L Chao, PhD

Principal Investigator

University of California, San Francisco

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials